TumoTest™ - Circulating Tumor Cell Test

TumoTest™ is an advanced blood-based circulating tumor cell test designed for confirmed cancer patients who require deeper cancer monitoring, treatment-response tracking, and personalized oncology planning.

Cancer is not only defined by the tumour seen on imaging. In many cases, cancer-related cells may circulate in the bloodstream and provide important information about disease activity, tumour behaviour, aggressiveness, and possible response to ongoing treatment.

TumoTest™ is developed to help doctors better understand what is happening beyond conventional scans and tumour markers by analysing circulating tumor cells, also known as CTCs, from a blood sample.

This makes TumoTest™ a valuable monitoring tool for patients undergoing doctor-led cancer management.

WHAT TUMOTEST™ IS?

TumoTest™ is a Circulating Tumor Cell Test.

Circulating Tumor Cells, or CTCs, are cancer-related cells that may detach from a primary tumour or metastatic site and enter the bloodstream.

By analysing these cells, TumoTest™ helps provide additional insight into:

• cancer-cell presence in circulation
• cancer-cell characteristics
• tumour behaviour
• disease activity
• treatment response
• possible aggressiveness
• metastatic potential

TumoTest™ helps detect and study cancer-related cells circulating in the blood.

It is not a general cancer screening test for healthy individuals. It is mainly designed for patients with confirmed cancer diagnosis or patients under doctor-led oncology monitoring.

HOW TUMOTEST™ WORKS?

The process begins with a blood sample.

The sample is analysed to identify and evaluate circulating tumor cells. These cells may carry useful information about the patient’s current cancer status.

Through CTC analysis, doctors can obtain a clearer picture of how the cancer may be behaving at that point in time.

TumoTest™ may help evaluate:

• whether circulating tumor cells are present
• how many CTCs are detected
• whether the CTC level is changing over time
• whether cancer-cell characteristics suggest higher or lower activity
• whether treatment appears to be reducing cancer-cell burden
• whether further treatment planning should be considered

This allows cancer monitoring to become more dynamic, rather than depending only on imaging or routine tumour markers.

WHY CIRCULATING TUMOR CELLS MATTER?

Cancer cells may not remain only in one location.

Some cancer cells can enter the bloodstream and travel through the body. These circulating tumor cells may provide important biological information about cancer progression, treatment response, and metastatic behaviour.

Monitoring CTCs can help doctors understand whether the cancer appears to be:

• responding to treatment
• remaining active
• changing in behaviour
• showing signs of higher aggressiveness
• requiring closer monitoring
• needing further investigation or treatment adjustment

TumoTest™ supports this by helping provide a blood-based view of cancer-related cellular activity.

WHAT MAKES TUMOTEST™ DIFFERENT?

• Blood-Based Cancer Monitoring
  • TumoTest™ uses a blood sample to study circulating tumor cells, offering an additional layer of information beyond conventional tumour markers.
• Focuses on Confirmed Cancer Cases
  • TumoTest™ is designed for patients with confirmed cancer diagnosis, especially those who need monitoring during or after treatment.
• Tracks Cancer-Cell Activity
  • Instead of only looking at tumour size, TumoTest™ helps review cancer-cell activity in circulation.
• Supports Treatment Response Review
  • A reduction in CTC number or improvement in cancer-cell characteristics may help support the assessment of treatment response.
• Provides Deeper Biological Insight
  • TumoTest™ may provide information related to cancer-cell behaviour, including aggressiveness, stemness, and metastatic potential.
• Supports Personalized Oncology Planning
  • The result may help doctors decide whether the patient requires continued monitoring, additional investigation, or further treatment planning.

KEY BENEFITS

• Monitors Circulating Tumor Cells
  • Helps detect and evaluate cancer-related cells circulating in the bloodstream.
• Supports Treatment Response Tracking
  • Can be used to compare changes before, during, or after treatment.
• Provides Additional Insight Beyond Tumour Markers
  • Gives doctors another layer of biological information beyond routine blood tumour markers.
• Helps Understand Cancer Behaviour
  • May provide information related to tumour aggressiveness, cancer-cell characteristics, and metastatic activity.
• Useful for Ongoing Cancer Management
  • Supports monitoring in patients undergoing chemotherapy, immunotherapy, targeted therapy, integrative oncology support, or post-treatment follow-up.
• Supports Advanced Personalized Care
  • Can be used as part of a broader precision oncology workflow to guide doctor-led decision-making.

WHO TUMOTEST™ IS DESIGNED FOR?

TumoTest™ is designed for confirmed cancer patients who need advanced monitoring and deeper cancer-cell insight.

It may be considered for patients who:

• have a confirmed cancer diagnosis
• are currently undergoing cancer treatment
• have completed treatment and require monitoring
• need treatment response assessment
• have unclear tumour marker results
• want deeper cancer-cell activity tracking
• are being evaluated for personalized oncology support
• require additional information before advanced treatment planning
• need monitoring of disease activity over time

TumoTest™ may be useful in doctor-led cancer management where CTC information can support clearer case understanding.

WHEN TUMOTEST™ MAY BE RECOMMENDED?

TumoTest™ may be considered:

• before starting a new treatment plan
• during ongoing cancer treatment
• after chemotherapy, immunotherapy, targeted therapy, or other oncology care
• when tumour markers are unclear or insufficient
• when imaging results need additional biological context
• during follow-up monitoring
• before considering advanced personalized oncology support
• when doctors need blood-based cancer-cell information

For patients on active chemotherapy, blood draw timing should be planned carefully under professional guidance, usually during an appropriate gap between treatment cycles.

WHAT THE RESULT MAY SHOW?

TumoTest™ may provide information such as:

• presence of circulating tumor cells
• CTC count
• cancer-cell characteristics
• tumour activity indicators
• changes compared to previous results
• possible treatment-response pattern
• biological signs linked to cancer aggressiveness
• indicators that may support further oncology planning

A falling CTC number or improvement in cancer-cell characteristics may help support the impression that a treatment approach is working. However, interpretation must always be done by a qualified medical professional together with imaging, tumour markers, symptoms, and clinical findings.

HOW TUMOTEST™ SUPPORTS PERSONALIZED ONCOLOGY

Every cancer behaves differently.

Two patients with the same diagnosis may have different circulating tumor cell profiles, different response patterns, and different levels of cancer-cell activity.

TumoTest™ helps doctors move beyond a one-size-fits-all view by providing blood-based information on the patient’s actual cancer-cell behaviour.

This may support more informed decisions on:

• monitoring frequency
• treatment response
• further investigation
• suitability for advanced oncology support
• follow-up planning
• personalized treatment discussion

SAMPLE & PROFESSIONAL WORKFLOW

TumoTest™ is performed through a professional blood collection process.

The general workflow may include:

1. Doctor consultation and case review
2. Blood sample collection
3. Sample handling and shipment according to protocol
4. Laboratory analysis of circulating tumor cells
5. Report generation
6. Doctor-led interpretation
7. Follow-up planning based on the patient’s overall condition

The result should not be interpreted in isolation. It should be reviewed together with the patient’s diagnosis, imaging reports, tumour markers, current treatment, medications, symptoms, and overall clinical status.

IMPORTANT NOTICE

TumoTest™ is a circulating tumor cell test intended for professional use and doctor-led interpretation.

It is not intended to diagnose cancer as a standalone test, treat cancer, cure cancer, or prevent cancer. Results must be interpreted by qualified medical professionals and reviewed together with the patient’s clinical history, imaging, laboratory findings, treatment status, and overall medical condition.

TumoTest™ is designed to support cancer monitoring and personalized oncology planning, not replace specialist oncology consultation or standard medical care.